Novartis To Pay $30 Million To Health Plans, Consumers Over Exforge Antitrust Claims
By Brendan Pierson (Reuters) – Swiss drugmaker Novartis AG has agreed to pay $30 million to settle claims by health plans and consumers that it schemed to delay the U.S. launch of generic competition for its Exforge hypertension drug. In a motion filed in Manhattan federal court Wednesday, lawyers for the plaintiffs said the proposed…
